West Nile virus vaccine - Crucell

Drug Profile

West Nile virus vaccine - Crucell

Alternative Names: PER.C6 cell line-based West Nile virus vaccine - Crucell; Whole-killed West Nile Virus Vaccine - Crucell

Latest Information Update: 06 Mar 2008

Price : $50

At a glance

  • Originator Crucell
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued West Nile virus infections

Most Recent Events

  • 12 Feb 2008 Discontinued - Phase-I for West Nile virus infections prevention in Belgium (IM)
  • 02 Feb 2007 Clinical data added to the adverse events section
  • 13 Jun 2003 Preclinical trials in West Nile virus infections in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top